TriangleJZP3507 (NCT07533942)
JZP3507 trial for Meningioma (NCT07533942). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with progressive grade 2 or 3 meningioma after standard care failed, was unsuitable or was declined. Prior ONC206 or dordaviprone is excluded.
The idea: test oral ONC206, also called JZP3507, twice daily on three consecutive days each week. It blocks DRD2 growth signals and activates ClpP, an enzyme that breaks down proteins inside the cell's energy-producing structures. This is intended to disrupt cancer-cell survival. Scans assess tumor response.
This phase 2 study plans 30 patients. Jazz Pharmaceuticals sponsors it; six US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.